, Singapore

Venture Corporation's profit rises 61% to $69.8m in Q2

This brings Venture’s 1H17 profits to $118.4m.

Venture Corporation’s profits surged 61% YoY from $43.4m to $69.8m in Q2.

For 1H17, the company’s PATMI, which formed 57.3% of OCBC’ Investment Research’s FY17 forecasts, rose 49.5% YoY to $118.4m on the back of a 41.3% growth in revenue to $1.86b, on similar reasons as 2Q17.

OCBC Investment Research noted that revenue climbed by 48.3% from $683.3m to $1b. Its diversified customers and strong execution of programmes in prior quarters contributed to the revenue growth.

Venture’s operating expenses grew 46.8% to $931.2m, due to increased changes in finished goods and work-in-progress, and raw materials used, as well as employee benefits.

Analyst Eugene Chua commented, “VMS’ (Venture) 1H17 PBT and net margins improved by 0.6ppt and 0.4ppt to 7.8% and 6.4%, respectively, driven mainly by: 1) management’s impressive execution of its strategy to pursue value creation for its customers, and 2) continuous efforts to increase productivity and efficiency.”
 

Join Singapore Business Review community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

Top News

DBS and OCBC expected to deliver steady Q1 net profits
Their net interest margins will ease as a result of their Hong Kong loans.
Singapore's maritime cluster navigates towards digital, green future
Adapting to emerging challenges, such as the adoption of alternative fuels, is deemed crucial for the country's maritime sector.
SCG and A*STAR unveil joint labs for cellular immunotherapy enhancement
The partnership has a funding of nearly $30m supported under Singapore's Research, Innovation and Enterprise 2025 plan.
Healthcare